A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Inclusion Criteria

• Subject is male or female, >= 20 years of age.
• Institutional Review Board-approved written informed consent form is signed and dated by the subject.
• Other protocol-defined inclusion criteria may apply.

For subjects with moderate to severe chronic plaque psoriasis (PSO)

• Chronic plaque psoriasis for at least 6 months.
• Baseline Psoriasis Activity and Severity Index (PASI) >=12 and Body Surface Area (BSA) affected by PSO >=10% and Physician's Global Assessment (PGA) score of 3 or higher.
• Candidates for systemic PSO therapy and/or phototherapy and/or chemophototherapy.

For subjects with generalized pustular PSO or erythrodermic PSO

• Diagnosis of generalized pustular PSO or erythrodermic PSO at Screening.
• History of plaque-type PSO if subjects have a diagnosis of erythrodermic PSO.
• Baseline BSA affected by PSO >=80% if subjects have a diagnosis of erythrodermic PSO.

Exclusion Criteria

• Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study or within 5 months following last dose of study drug. Male subject who is planning a partner pregnancy during the study or within 5 months following the last dose of study drug.
• Subject has guttate psoriasis or drug-induced psoriasis. For subjects with moderate to severe plaque psoriasis, erythrodermic or pustular forms of psoriasis also are excluded.
• History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol. Also, subjects with a high risk of infection in the Investigator's opinion.
• History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease.
• History of other malignancy or concurrent malignancy as described in the protocol.
• Class III or IV congestive heart failure
• History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis).
• Subject has any other condition which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study.
• Concurrent medication restrictions as described in the protocol.
• Subject with known tuberculosis (TB) infection, at high risk of acquiring TB infection, or with untreated latent tuberculosis infection (LTBI) or current or history of nontuberculous mycobacterial (NTMB) infection.
• Subject has any protocol defined clinically significant laboratory abnormalities at the screening
• Other protocol-defined exclusion criteria may apply.